Expert Insights

Sponsored
In this video, Dr Graff talks about how the treatment landscape for CLL has evolved in recent years, especially with the introduction of acalabrutinib.
Sponsored
In this video, Dr Goy discusses recent innovations in the treatment of patients with MCL.
Premal Lulla, MBBS, discusses his team's study on the use of nonengineered T-cells for the treatment of patients with HL and NHL.
Mridula George, MD, Rutgers Cancer institute of New Jersey, discusses the addition of HER2 targeted agents within the last two decades that have been studied in the metastatic, adjuvant, and the…
Dr Stull discusses the INSIGHT MM observational study examining ixazomib plus lenalidomide and dexamethasone for relapsed/refractory MM.
Mridula George, MD, Rutgers Cancer Institute of New Jersey, discusses her approach of early-stage HER2 positive breast cancer treatment.
Rachel McConachie, RN, BSN, Dignity Health Cancer Institute of Greater Sacramento, discusses how her cancer center has adapted to providing patients with telemedicine-driven genetic counseling.
Teresa Boitano, MD, discusses an analysis comparing minimally-invasive hysterectomy vs open radical hysterectomy for early-stage cervical cancer.

Interviews

Rachel McConachie, RN, BSN, Dignity Health Cancer Institute of Greater Sacramento, discusses how her cancer center has adapted to providing patients with telemedicine-driven genetic counseling.
Pek Lum, PhD, discusses an AI-driven pharmaceutical company's efforts of mitigating cancer therapy toxicities through an AI engine.
Todd Cohen, MD, highlights how certain patients with prostate cancer may be able to forgo receipt of combined ADT.
Ehab L. Atallah, MD, discusses the findings of a study which looked at outcomes after TKI cessation in patients with CML.

Webcasts

Sponsored
In this video, Dr Danilov discusses the use of acalabrutinib as a treatment option for patients with CLL, SLL, and MCL.
Sponsored
In this video, Dr Graff talks about how the treatment landscape for CLL has evolved in recent years, especially with the introduction of acalabrutinib.
Sponsored
In this video, Dr Goy discusses recent innovations in the treatment of patients with MCL.
Premal Lulla, MBBS, discusses his team's study on the use of nonengineered T-cells for the treatment of patients with HL and NHL.

Resources

Detailed information about the presentation, diagnosis, staging, prognosis, and treatment of all types of childhood NHL and lymphoproliferative disease.
Non-Hodgkin lymphoma treatment options include chemotherapy, radiation, targeted therapy, plasmapheresis, surveillance, stem cell transplant, and surgery. Get comprehensive information on Non-Hodgkin…
Chronic myelogenous leukemia treatments include tyrosine kinase inhibitors, high-dose therapy with allogeneic transplantation, and other medications. Get detailed information about chronic…
Breast cancer is the most common cancer in pregnant and postpartum women and occurs in about 1 in 3,000 pregnant women. The average patient is between the ages of 32 years and 38 years. Because many…

Debates and Roundtables

In the third part of this roundtable, Steven Horwitz, MD; Alison Moskowitz, MD; and Barbara Pro, MD, discuss notable advancements in the standard treatment of T-cell lymphoma.
In the second part of this roundtable, Steven Horwitz, MD; Alison Moskowitz, MD; and Barbara Pro, MD, discuss the background, findings, and importance of the ECHELON-2 clinical trial.
In the first part of this roundtable, Steven Horwitz, MD; Alison Moskowitz, MD; and Barbara Pro, MD, discuss the challenges of treating patients with T-cell lymphoma.
In the second installment of this roundtable discussion, experts sat down with Oncology Learning Network to discuss use of liquid biopsies to detect treatment resistance in lung cancer, areas for…
Stay in the know.
OncNet Newsletter